Ginkgo Bioworks Holdings Inc vs Keel Infrastructure Corp. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.7 (market cap $763.64M), while Keel Infrastructure Corp. Common Stock trades at $3.11 (market cap $1.93B). The key difference: Keel Infrastructure Corp. Common Stock is far larger — about 2.5× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Keel Infrastructure Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Keel Infrastructure Corp. Common Stock for 0 Days on average.
| DNA | KEEL | |
|---|---|---|
Market Cap | $763.64M | $1.93B |
Volume | 3,204,177 | 30,868,523 |
Sector | Health | Technology |
52-Week High | $15.83 | $6.66 |
52-Week Low | $5.48 | $1.71 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $865.59M | $2.25B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →